Coronavirus Update: Pfizer/BioNTech Vaccine Effective Against Omicron

AstraZeneca Antibody Cocktail Gets EUA For PrEP

Also, AstraZeneca scores an emergency use authorization from the FDA for its COVID-19 PrEP antibody Evusheld, while Merck files for Japanese approval of molnupiravir.

The likelihood that most people will need at least a third dose of Pfizer Inc. and BioNTech SE’s messenger RNA-based COVID-19 vaccine Comirnaty became more apparent as the companies announced data showing that a third dose provided neutralized antibody titers against the new Omicron variant, while the standard two-dose series showed significantly reduced neutralization.

The remaining question now is how effective other vaccines are against Omicron, especially amid lingering fears that the variant’s spread...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip